Trial Profile
A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Terbinafine (Primary)
- Indications Onychomycosis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 09 Sep 2014 New trial record